iNOs-IN-3
iNOs-IN-3 (Compound 2d) is an orally active nitric oxide synthase (iNOS) inhibitor (IC50=3.342 µM). iNOs-IN-3 shows anti-inflammatory activity and can be used in LPS-induced acute lung injury (ALI) research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2241674-94-0
- Formule: C27H24N2O5S
- Masse moléculaire:488.55
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
IC50: 3.342 µM (iNOS)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RAW264.7 | IC50 |
3.342 μM
Compound: 2d
|
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide synthase production measured after 24 hrs by ELISA
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide synthase production measured after 24 hrs by ELISA
|
[PMID: 33065432] |
iNOs-IN-3 (25 μM; 24 h) inhibits LPS-induced RAW 264.7 cells[1].
iNOs-IN-3 (12.5 μM; 24 h) can decrease the expression of iNOS[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW 264.7 microphages
-
Concentration:25 μM
-
Incubation Time:24 hours
-
Result:Showed higher inhibitory activity (IC50=14.72 µM) in LPS-induced RAW 264.7 cells.
-
Cell Line:RAW 264.7 microphages
-
Concentration:12.5 μM
-
Incubation Time:24 hours
-
Result:Inhibited the LPS-induced mRNA expression of iNOS obviously.
-
Cell Line:RAW 264.7 microphages
-
Concentration:12.5 μM
-
Incubation Time:24 hours
-
Result:Inhibited the expression of TNF-α, IL-6, and IL-1β at 12.5 µM.
iNOs-IN-3 (oral administration; 3.125 mg/kg, 6.25 mg/kg, 12.5 mg/kg; once) protects against LPS-induced acute lung injury[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Xylene-induced mice[1]
-
Dosage:12.5 mg/kg
-
Administration:Oral administration; 12.5 mg/kg; once
-
Result:Showed better activity than the positive control.
-
Animal Model:LPS-induced acute lung injury (ALI) mice[1]
-
Dosage:3.125 mg/kg, 6.25 mg/kg, 12.5 mg/kg
-
Administration:Oral administration; 3.125 mg/kg, 6.25 mg/kg, 12.5 mg/kg; once
-
Result:Attenuated the pathological lesions dose-dependently, such as decreased inflammatory infiltration and pulmonary congestion. Inhibited LPS-induced lung edema dose-dependently.
Chemical Information
-
CAS No. 2241674-94-0
-
Masse moléculaire 488.55
-
Formule C27H24N2O5S
-
SMILES
O=C1OC2=CC=CC(OS(=O)(C3=CC=CC4=C(N(C)C)C=CC=C43)=O)=C2N1CCC5=CC=CC=C5
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
iNOs-IN-3 Related Classifications
HY-150055 Related Classifications
Powered by Bioz